CytoDyn Inc.
CYDY
$0.204
$0.0031.49%
OTC PK
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -45.19% | -0.74% | -40.33% | 8.75% | -7.20% |
| Depreciation & Amortization | -28.57% | -50.00% | -50.00% | -60.00% | -41.67% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.25% | 9.09% | -44.75% | 75.50% | -12.93% |
| Operating Income | -17.25% | -9.09% | 44.75% | -75.50% | 12.93% |
| Income Before Tax | 60.08% | 50.14% | 266.17% | 9.92% | 13.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 60.08% | 50.14% | 266.17% | 9.92% | 13.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.08% | 50.14% | 266.17% | 9.92% | 13.01% |
| EBIT | -17.25% | -9.09% | 44.75% | -75.50% | 12.93% |
| EBITDA | -17.35% | -9.23% | 44.74% | -75.86% | 12.84% |
| EPS Basic | 66.40% | 59.62% | 228.68% | 18.75% | 26.90% |
| Normalized Basic EPS | 42.22% | 40.48% | 50.98% | 50.46% | 48.86% |
| EPS Diluted | 66.40% | 59.62% | 224.03% | 18.75% | 37.50% |
| Normalized Diluted EPS | 42.22% | 40.48% | 52.94% | 50.46% | 48.86% |
| Average Basic Shares Outstanding | 25.05% | 27.36% | 22.90% | 11.00% | 18.02% |
| Average Diluted Shares Outstanding | 25.05% | 27.36% | 29.74% | 11.00% | 18.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |